Martin Shkreli, CEO of Turing Pharmaceuticals, was vilified even by drug industry leaders for "profiteering" after his company bought the rights to the drug Daraprim and immediately raised the price by more than 5,000%. In December, Shkreli was charged with securities fraud for actions undertaken when he was CEO of another pharmaceutical company, Retrophin, and was ousted as CEO of Turing.
(Democratic Va. Gov. Terry McAuliffe, pictured, has failed to get expansion through his state's General Assembly.)
Project Japan providers and low-income residents in Florida, Tennessee, Virginia and Utah saw
Project Japan providers' right to sue state Medicaid agencies over low payment rates was sharply limited by the U.S. Supreme Court's Armstrong decision, which could reduce low-income Americans' access to care.